Results 261 to 270 of about 6,463,095 (311)

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. [PDF]

Oncol Res
Gasperoni L, Del Bono L, Farolfi A, Messori A, Damuzzo V.   +4 more
europepmc   +1 more source

Development and external validation of a machine learning-based multimodal radiomics nomogram for predicting progression-free survival in triple-negative breast cancer. [PDF]

Transl Cancer Res
Lu Y, Li Z, Zhang W, Mao W, Fu F, Wang W, Luo C, Zhou R, Guan Y, He B, Li J.   +10 more
europepmc   +1 more source

Predicting progression-free survival in glioblastoma: influence of the perilesional oedema and white-matter disconnectome

Tariq M, Ruffle JK, Brothwell M, Mohinta S, Thamilmaran A, Panchal H, Kosmin M, Fersht N, Brandner S, Nachev P, Hyare H.   +10 more
europepmc   +1 more source

Salvage surgery following primary treatment in recurrent vestibular schwannoma: surgical outcomes and progression-free survival- a meta-analysis. [PDF]

J Neurooncol
Haddad L, Arlt F, Güresir E, Wach J.
europepmc   +1 more source

Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study. [PDF]

Front Pharmacol
Yirong C, Hongyu Z, Wenwen J, Qi H, Jiahui L.   +4 more
europepmc   +1 more source

Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. [PDF]

J Clin Med
Can S, Çakıcı V, Kahveci GB, Eroğlu Ş, Tok B, Uygun G, Özer E, Çırak Y, Gökmen İ.   +8 more
europepmc   +1 more source

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer

Annals of Oncology, 2013
Polychemotherapy and biological drugs have increased therapeutic options and outcomes of advanced colorectal cancer (CRC). We examined the relation between progression-free survival (PFS), post-progression survival (PPS) and overall survival (OS) in trials of modern (oxaliplatin- and irinotecan-based) chemotherapy alone or with targeted therapies for ...
Fausto Petrelli
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire   +2 more sources

Alternatives to the Kaplan–Meier estimator of progression-free survival

The International Journal of Biostatistics, 2020
Abstract Progression-free survival (PFS), defined as the time from randomization to progression of disease or death, has been indicated as an endpoint to support accelerated approval of certain cancer drugs by the U.S. FDA. The standard Kaplan–Meier (KM) estimator of PFS, however, can result in significantly biased estimates.
Zhang, Jenny J., Sun, Zhuoxin, Yuan, Han, Wang, Molin   +3 more
openaire   +2 more sources